COVID-19 Monoclonal Antibody IV Therapy
COVID-19 Monoclonal Antibody IV Therapy
We now offer Monoclonal Antibody IV Therapy to treat COVID-19 positive patients with mild to moderate symptoms or for prophylaxis for those who have had exposure to COVID-19.
Monoclonal Antibody IV Therapy
This is a promising course of treatment that can reduce the amount of the SARS-CoV-2 virus in a person’s system.
- Shown to reduce Covid-19-related hospitalization
- Shown to reduce viral load
- Shown to reduce symptom severity
- FDA EUA Approved
Price: $999-$1,499
Who is eligible to receive monoclonal antibody IV therapy?
Monoclonal antibody treatment may be helpful for individuals who:
Have tested positive for COVID-19
Have been exposed to COVID-19
Are vaccinated OR unvaccinated
Are in high-risk environments
Frequently Asked Questions
What are monoclonal antibodies?
Monoclonal antibodies are lab-created proteins that mimic the ones our bodies produce to fight viruses. The antibodies defend the body by blocking Covid-19 viruses from attaching to human cells.